loss

Star Health Reports 21% YoY Profit Growth to 518 Cr; COR Improves by 170 bps in H1FY26 under IFRS

24% growth in fresh retail premiums Expense ratio improves to 29.7% from 31.1% (IFRS) CHENNAI, India, Oct. 29, 2025 /PRNewswire/…

2 months ago

South Korea’s Leading Hair Loss Treatment Company, AESMED Co., Ltd., to Participate in Cosmoprof Asia Hong Kong 2025

AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- AESMED…

2 months ago

JOY GROUP Completes Acquisition of Italian Dermatological Hair Care Brand Foltne

SHANGHAI, Oct. 21, 2025 /PRNewswire/ -- China's leading multi-brand beauty group JOY GROUP (Shanghai Juyi Cosmetics Co., Ltd.) has announced the completion…

2 months ago

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…

2 months ago

Indian Mobile Operators Help Online Businesses Combat Scams and Identity Theft Through New Federated Network Services, Supported by GSMA Open Gateway

New GSMA report shows more than half of Indian's have been scammed, with 14% reporting financial loss NEW DELHI, Oct.…

2 months ago

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

3 months ago

People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being

Results from a real-world survey suggest that semaglutide for weight management (Wegovy®) helped suppress food noise – unwanted and intrusive…

3 months ago

Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome

September 11, 2025 09:00 ET  | Source: Nacuity Pharmaceuticals, Inc. NPI-001 shows more than 50% reduction in photoreceptor loss caused…

3 months ago

Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment

Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for…

4 months ago

As Agentic AI Gains Traction, 86% of Enterprises Anticipate Heightened Risks, Yet Only 2% of Companies Meet Responsible AI Gold Standards

With 95% of enterprises facing incidents, Infosys research reveals wide gap between AI adoption and responsible AI readiness, exposing most…

4 months ago